Safety and satisfaction profile with the fixed combination of memantine-donepezil in patients diagnosed with moderate to severe Alzheimer's disease
DOI:
https://doi.org/10.29166/rfcmq.v49i1.5824Keywords:
Alzheimer's disease, safety, drug combination, memantine, donepezilAbstract
Introduction: Alzheimer's disease is a neurodegenerative disorder of insidious onset and slow progression. Epidemiologically it accounts for 60% to 70% of cases of dementia.
Objective: Determine the degree of satisfaction and safety with the fixed combination of memantine-donepezil for 6 months.
Materials and methods: A cross-sectional, observational, and analytical study was conducted based on a Real World Evidence (RWE) design to assess treatment satisfaction through Likert-scale questions of 31 patients who, as part of their regular treatment, received the fixed combination of memantine + donepezil once daily for six months before the administration of the satisfaction scale. Data collection took place from February to November 2021.
Results: 60% of adverse events were mild, 40% moderate. Tolerability after 3 months was perceived as very good or excellent by 81% of patients. At six months 87,1% rated the treatment as very good or excellent. Satisfaction with treatment at 3 months was, "mostly satisfied" or "totally satisfied" for 87,1%.
Discussion: Prevalence in the female gender of 77,4% higher than that reported for the whole country of 54,8%, reported comorbidities similar to those described in the literature. Tolerability rated as excellent compared to other studies which rated as good tolerability.
Conclusions: Administration of the fixed combination of memantine 14 mg + donepezil 10 mg or memantine 28 mg + donepezil 10 mg was a safe and well-tolerated option.
Downloads
Metrics
References
- Hogh P., Alzheimer's disease, Ugeskr Laeger [Internet]. 2017 [citado 28 Sep 2020]; 179(12): 505-508. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28330540/
- Lane CA, Hardy J, J M Schott, European Journal of Neurology [Internet]. 2018 [citado 28 Sep 2020]; 25(1):59-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28872215/
- Organización Mundial de la Salud (OMS) [Internet].2020 [citado 28 Sep 2020] Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/dementia
- González M., Fillat Y., Beatriz Peláez B., Pérez M., Plan Integral de Alzheimer y otras Demencias (2019-2023) [Internet]. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social; 2019 [citado 27 Sep 2020] Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/docs/Plan_Integral_Alhzeimer_Octubre_2019.pdf
- Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019 [citado 27 Sep 2020];103(2):263-293. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30704681/
- Evans S., Bhatt J., Comas A., D’Amico F., Farina N., Gaber S., Knapp M., Salcher M., Stevens M., Wilson E., World Alzheimer Report 2019: Attitudes to dementia. [Internet]. London: Alzheimer’s Disease International [citado 27 Sep 2020]; 1 -160 Disponible en: https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf
- Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis. Neurología 2017; 32(8): 523-532.
- Maestre GE, Mena LJ, Melgarejo JD, Aguirre-Acevedo DC, Pino-Ramírez G, Urribarrí M, Chacon IJ, Chávez CA, Falque-Madrid L, Gaona CA, Terwilliger JD, Lee JH, Scarmeas N., Incidence of dementia in elderly Latin Americans: results of the Maracaibo Aging Study. Alzheimers Dement 2018; 14(2): 140-147.
- Espinosa del Pozo, P., Garzon, Y., Velez, R., Batallas, E., Basantes, A., & Betancourt, J. Factores de riesgo y prevalencia de la demencia y enfermedad de Alzheimer en Pichincha – Ecuador (Estudio FARYPDEA). Revista de la Facultad de Ciencias Médicas (Quito). 2017; 37(1-2): 50-55. Recuperado a partir de http://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/1089.
- Gestión Digital. El Alzheimer afecta más a las mujeres en Ecuador. [Internet]. Quito: Multiplica ediciones. 25 septiembre 2018 [citado 27 Sep 2020]. Disponible en: https://www.revistagestion.ec/index.php/cifras/el-alzheimer-afecta-mas-las-mujeres-en-ecuador
- Hernandez M., Hidalgo M., Campaña de Mercadeo Social: Enfermedad de Alzheimer [Internet]. Quito: UNIVERSIDAD SAN FRANCISCO DE QUITO USFQ 2016 [citado 27 Sep 2020]. Disponible en: http://repositorio.usfq.edu.ec/bitstream/23000/6189/1/127736.pdf
- Briggs R, Kennelly SP, O'Neill D. Drug treatments in Alzheimer's disease. Clin Med. 2016; 16(3):247-253.
- Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. [Internet]. F1000Res. 2018 Jul 31;7:F1000 Faculty Rev-1161. [citado 27 Sep 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073093/pdf/f1000research-7-15791.pdf
- Calhoun A, King C, Khoury R, Grossberg GT. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2018;19(15):1711-1717
- Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). Int J Geriatr Psychiatry. 2017;32(12):1205-1216.
- Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195-203.
- Owen RT. Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia. Drugs Today (Barc). 2016;52(4):239-48.
- Dou K., Tan M., Tan C., Cao X., Hou X., Guo Q., Tan L., Mok V., Yu J. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126.
- Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, Chou KR. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One. 2017;12(8):e0183586
- Greig SL. Memantine ER/Donepezil: A Review in Alzheimer's Disease. CNS Drugs. 2015; 29(11):963-70.
- Soria Lopez JA, González HM, Léger GC. Alzheimer's disease. Handb Clin Neurol. [Internet]. 2019 [citado 28 Feb 2022]; 167:231-255. DOI: 10.1016/B978-0-12-804766-8.00013-3.
- Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS, Ivory JD, Khan PA, Yazdi F, Ghassemi M, Blondal E, Ho JM, Ng CH, Hemmelgarn B, Majumdar SR, Perrier L, Straus SE. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. J Am Geriatr Soc. [Internet]. 2018 [citado 28 Feb 2022]; 66(1):170-178. DOI: 10.1111/jgs.15069.
- Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, Iwata N. The efficacy and safety of memantine for the treatment of Alzheimer's disease. Expert Opin Drug Saf. [Internet]. 2018 [citado 01 Mar 2022];17(10):1053-1061. DOI: 10.1080/14740338.2018.1524870.
- Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. [Internet]. 2020 [citado 01 Mar 2022];10(11):e01831. DOI: 10.1002/brb3.1831.
- Ferreira TR, Lopes LC, Bergamaschi CC. Frequency and Severity of Adverse Drug Reactions to Medications Prescribed for Alzheimer's Disease in a Brazilian City: Cross-Sectional Study. Front Pharmacol. [Internet]. 2020 [citado 02 Mar 2022]; 15;11:538095. doi: 10.3389/fphar.2020.538095.
- Bago P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study. Cogn Behav Neurol. [Internet] 2021 [citado 02 Mar 2022]; Dec 2;34(4):288-294. DOI: 10.1097/WNN.0000000000000285.
- Zhang N, Gordon ML. Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients. Clin Interv Aging. [Internet] 2018 [citado 03 Mar 2022]; 11;13:1963-1970. DOI: 10.2147/CIA.S159920.
- Zhang T, Liu N, Cao H, Wei W, Ma L, Li H. Different Doses of Pharmacological Treatments for Mild to Moderate Alzheimer's Disease: A Bayesian Network Meta-Analysis. Front Pharmacol. [Internet] 2020 [citado 03 Mar 2022]; 26;11:778. DOI: 10.3389/fphar.2020.00778
- Cao Y, Qian L, Yu W, Li T, Mao S, Han G. Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer's disease and chronic obstructive pulmonary disease: a retrospective observational study. J Int Med Res. [Internet] 2020 [citado 05 Mar 2022]; 48(2):300060520902895. DOI 10.1177/0300060520902895
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sandro Patricio Romero Proaño
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.